BioCentury | Mar 3, 2017
Clinical News

Taksta: Ph III data

...patients in the ITT population of a double-blind, U.S. Phase III trial showed that oral Taksta...
...two doses of 1,500 mg oral Taksta 12 hours apart followed by 600 mg oral Taksta...
...the agency to treat ABSSSIs. Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Product: Taksta sodium fusidate, fusidic acid (CEM-102...
BioCentury | Feb 28, 2017
Clinical News

Cempra sags after reporting Solithera setbacks

...ended 2016 with $231.6 million in cash. Last week, Cempra said Gram-positive bacterial antibiotic Taksta fusidic acid...
...skin structure infections (ABSSSIs) (see BioCentury Extra, Feb. 24) . Jaime De Leon CEM-101 CEM-102 fusidic acid IV Solithera IV solithromycin Oral Solithera oral solithromycin sodium fusidate Taksta Cempra...
BioCentury | Feb 24, 2017
Clinical News

Cempra gains on Phase III ABSSSIs data

...Cempra Inc. (NASDAQ:CEMP) gained $0.90 (29%) to $4.05 on Friday after Taksta fusidic acid met the primary...
...structure infections. In the trial’s intent-to-treat (ITT) population (n=716), 87.2% of patients treated with oral Taksta...
...two doses of 1,500 mg oral Taksta 12 hours apart followed by 600 mg oral Taksta...
BioCentury | Jan 4, 2016
Clinical News

Taksta sodium fusidate: Phase III started

...Cempra began a double-blind, placebo-controlled, U.S. Phase III trial to compare oral Taksta twice daily vs...
...oral Zyvox linezolid twice daily for 10 days in about 712 patients. Patients in the Taksta...
...and 600 mg thereafter. Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Product: Taksta sodium fusidate, fusidic acid ( CEM-102...
BioCentury | Sep 28, 2015
Clinical News

Taksta sodium fusidate regulatory update

...FDA granted Qualified Infectious Disease Product (QIDP) designation to Taksta sodium fusidate from Cempra to treat acute...
...structure infections (ABSSSI). By year end, Cempra plans to start a Phase III trial of Taksta...
...outside of the U.S. Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Product: Taksta sodium fusidate (fusidic acid) ( CEM-102...
BioCentury | Dec 12, 2013
Targets & Mechanisms

ClpPing persistence

...macrolide antibiotic, is in Phase III testing for community-acquired bacterial pneumonia (CABP). The company's Taksta (fusidic acid...
BioCentury | Nov 4, 2013
Clinical News

Taksta sodium fusidate regulatory update

...FDA granted Orphan Drug designation to Cempra's Taksta to treat prosthetic joint infections. The oral antibiotic...
...The oral antibiotic active against Gram-positive bacteria is in Phase II testing for the indication. Taksta...
...and skin structure infections (cSSSIs). Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Product: Taksta sodium fusidate ( CEM-102...
BioCentury | Dec 24, 2012
Clinical News

Sodium fusidate: Phase II started

...Cempra began an open-label, U.S. Phase II trial in about 50 patients to compare oral CEM-102...
...1,500 mg CEM-102 twice daily on day 1 and 600-900 mg CEM-102 twice daily thereafter. CEM-102...
...structure infections (cSSSIs). Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Product: Sodium fusidate ( Taksta ) ( CEM-102...
BioCentury | Oct 17, 2011
Finance

First in fall

...use the funds for Phase III testing of two candidates in 2H12: solithromycin and Taksta fusidic acid...
...fusidic acid. Solithromycin ( CEM-101 ) is an oral macrolide antibiotic for community-acquired bacterial pneumonia (CABP). Taksta...
...CEM-101 ) is an oral macrolide antibiotic for community-acquired bacterial pneumonia (CABP). Taksta fusidic acid ( CEM-102...
BioCentury | Oct 14, 2011
Financial News

Cempra planning IPO

...CEM-101 ), a macrolide antibiotic, for community-acquired bacterial pneumonia (CABP); and Taksta fusidic acid ( CEM-102...
Items per page:
1 - 10 of 17